TY - GEN
T1 - Preparation, characterization and in vitro release study of microcapsule simvastatin using biodegradable polymeric blend of poly(L-lactic acid and poly(ɛ-caprolactone) with double emulsifier
AU - Kusumasari, Findi Citra
AU - Samada, Lukmanul Hakim
AU - Budianto, Emil
N1 - Publisher Copyright:
© 2020 Trans Tech Publications Ltd, Switzerland.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Simvastatin is a cholesterol-lowering agent that inhibits the microsomal activity of 3-hydroxy-3-methylglutaril-CoA-reductase (HMG-CoA reductase), enzyme that contributes in biosynthesis cholesterol. Simvastatin has short half-life elimination about 2 hours and low solubility, this condition makes its bioavailability to be quite small. Simvastatin has adverse effect such as myopathy and rhabdomyolysis because of higher dose consumption of simvastatin. Controlled drug delivery system is needed to reduce the adverse effect. One of method that is used in drug delivery system is encapsulation using biodegradable polymer such as poly(L-lactic acid) and poly(ɛ-caprolactone). PLLA and PCL was blended with fix composition PLLA: PCL 60: 40 (%w/w) by solvent evaporation technique using Tween 80 and Span 80 as emulsifier. Based on the optimization, the best encapsulation efficiency microcapsules were obtained at concentration of Tween 80 0.025% (v/v), Span 80 1% (v/v) with stirring speed at 900 rpm for 1 hour. The encapsulation efficiency was 83.67%. The best microcapsules were dissolved in dissolution media to get drug release profile. The percentage of drug release at pH 1.2 was 0.86% for 3 hours and in the phosphate buffer solution pH 7.4 for 12.22% for 52 hours.
AB - Simvastatin is a cholesterol-lowering agent that inhibits the microsomal activity of 3-hydroxy-3-methylglutaril-CoA-reductase (HMG-CoA reductase), enzyme that contributes in biosynthesis cholesterol. Simvastatin has short half-life elimination about 2 hours and low solubility, this condition makes its bioavailability to be quite small. Simvastatin has adverse effect such as myopathy and rhabdomyolysis because of higher dose consumption of simvastatin. Controlled drug delivery system is needed to reduce the adverse effect. One of method that is used in drug delivery system is encapsulation using biodegradable polymer such as poly(L-lactic acid) and poly(ɛ-caprolactone). PLLA and PCL was blended with fix composition PLLA: PCL 60: 40 (%w/w) by solvent evaporation technique using Tween 80 and Span 80 as emulsifier. Based on the optimization, the best encapsulation efficiency microcapsules were obtained at concentration of Tween 80 0.025% (v/v), Span 80 1% (v/v) with stirring speed at 900 rpm for 1 hour. The encapsulation efficiency was 83.67%. The best microcapsules were dissolved in dissolution media to get drug release profile. The percentage of drug release at pH 1.2 was 0.86% for 3 hours and in the phosphate buffer solution pH 7.4 for 12.22% for 52 hours.
KW - Dissolution
KW - Encapsulation efficiency
KW - Microcapsule
KW - O/w solvent evaporation
KW - Poly(L-lactic acid)
KW - Poly(ɛ-caprolactone)
KW - Simvastatin
KW - Span 80
KW - Tween 80
UR - http://www.scopus.com/inward/record.url?scp=85081170479&partnerID=8YFLogxK
U2 - 10.4028/www.scientific.net/MSF.977.178
DO - 10.4028/www.scientific.net/MSF.977.178
M3 - Conference contribution
AN - SCOPUS:85081170479
SN - 9783035716320
T3 - Materials Science Forum
SP - 178
EP - 183
BT - Metal Materials Processes and Manufacturing
A2 - Jung, Dong-Won
PB - Trans Tech Publications Ltd
T2 - 2nd International Conference on Metal Material Processes and Manufacturing, ICMMPM 2019
Y2 - 30 July 2019 through 31 July 2019
ER -